Content area
Full text
Allergan, Inc. announces the introduction of Acular PF (ketorolac tromethamine ophthalmic solution) 0.5% Preservative-Free. In November 1997, Allergan was given the U.S. Food and Drug Administration (FDA) clearance to market Acular PF, the first unit-dose, preservative-free topical nonsteroidal anti-inflammatory (NSAID) in the U.S., for the reduction of ocular pain and photophobia following incisional refractive surgery.
The preserved, multi-dose form is indicated for the treatment of postoperative inflammation following cataract extraction, and is the medication most frequently prescribed by ophthalmologists and primary care physicians for ocular itch associated with seasonal allergic conjunctivitis.
"Topical NSAIDs now play several important roles in ophthalmic surgery," said Vance Thompson, MD, director of refractive surgery, Sioux Valley Hospital, Sioux Falls, SD. Thompson was a principle investigator in clinical trials of Acular PF. "Acular PF gives us just the amount...